Abionyx Pharma SA - ESG Rating & Company Profile powered by AI
Other corporations in the scoring peer group for Abionyx Pharma SA are displayedin the table. The webpage contains a free Environmental, Social and Governance assessment covering Abionyx Pharma SA. The ESG score covers seventeen UN Sustainable Development Goals including: 'No Poverty', 'Sustainable Cities & Communities' and 'Life below Water'.
Abionyx Pharma SA in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.1; made up of an environmental score of 8.0, social score of 8.0 and governance score of 5.3.
7.1
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| 315 | Pluristem Therapeutics Inc | 7.2 | High |
| 315 | Regeneron Pharmaceuticals Inc | 7.2 | High |
| 326 | Abionyx Pharma SA | 7.1 | High |
| 326 | BOD Australia Ltd | 7.1 | High |
| 326 | Abliva AB | 7.1 | High |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Abionyx Pharma SA have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Abionyx Pharma SA disclose current and historical energy intensity?
Sign up for free to unlockDoes Abionyx Pharma SA report the average age of the workforce?
Sign up for free to unlockDoes Abionyx Pharma SA reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Abionyx Pharma SA disclose its ethnicity pay gap?
Sign up for free to unlockDoes Abionyx Pharma SA disclose cybersecurity risks?
Sign up for free to unlockDoes Abionyx Pharma SA offer flexible work?
Sign up for free to unlockDoes Abionyx Pharma SA have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Abionyx Pharma SA disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Abionyx Pharma SA conduct supply chain audits?
Sign up for free to unlockDoes Abionyx Pharma SA disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Abionyx Pharma SA conduct 360 degree staff reviews?
Sign up for free to unlockDoes Abionyx Pharma SA disclose the individual responsible for D&I?
Sign up for free to unlockDoes Abionyx Pharma SA disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Abionyx Pharma SA disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Abionyx Pharma SA disclose water use targets?
Sign up for free to unlockDoes Abionyx Pharma SA have careers partnerships with academic institutions?
Sign up for free to unlockDid Abionyx Pharma SA have a product recall in the last two years?
Sign up for free to unlockDoes Abionyx Pharma SA disclose incidents of discrimination?
Sign up for free to unlockDoes Abionyx Pharma SA allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Abionyx Pharma SA issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Abionyx Pharma SA disclose parental leave metrics?
Sign up for free to unlockDoes Abionyx Pharma SA disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Abionyx Pharma SA disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Abionyx Pharma SA disclose the pay ratio of women to men?
Sign up for free to unlockDoes Abionyx Pharma SA support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Abionyx Pharma SA disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Abionyx Pharma SA reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Abionyx Pharma SA involved in embryonic stem cell research?
Sign up for free to unlockDoes Abionyx Pharma SA disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Abionyx Pharma SA disclose its waste policy?
Sign up for free to unlockDoes Abionyx Pharma SA report according to TCFD requirements?
Sign up for free to unlockDoes Abionyx Pharma SA disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Abionyx Pharma SA disclose energy use targets?
Sign up for free to unlockDoes Abionyx Pharma SA disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Abionyx Pharma SA have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Abionyx Pharma SA
These potential risks are based on the size, segment and geographies of the company.
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was founded in 2005 and is based in Balma, France.